Sweet vaccines are novel carbohydrate based vaccines being developed by the company Malcisbo. The first targets are unmet medical needs such as Campylobacter induced food poisoning and parasitic infections by the blood sucking stomach worm Hemonchus in sheep causing losses in food production.
Malcisbo has developed a proprietary target discovery platform which it will use in combination with glycoengineering technologies to provide novel and efficient glycoconjugate vaccines. The discovery platform will generate a constant outflow of novel vaccines for unmet human and veterinary medical needs.
Further projects are affordable vaccines to protect people in underdeveloped areas against parasitic worm infections.
Company Details
- Employees
- 5
- Phone
- 41 44 633 78 87
- in****@****sbo.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- malcisbo.com
Malcisbo Ltd. Questions
Malcisbo Ltd.'s helpline number is 41 44 633 78 87
Malcisbo Ltd.'s website is malcisbo.com
Malcisbo Ltd.'s LinkedIn profile is https://ch.linkedin.com/company/malcisbo-ltd.
Malcisbo Ltd. has
5 employees.
View email and phone details for 5
employees at Malcisbo Ltd..
Malcisbo Ltd.'s industry is
Biotechnology Research
Malcisbo Ltd.'s top competitors are
Deciphera Pharmaceuticals,
Mirum Pharmaceuticals, Inc.,
Azurecell,
Sebio Gmbh,
Numab Therapeutics Ag,
Adularia,
Endogena Therapeutics, Inc.,
Tégrégé,
Mobipolter,
Neurotune Ag.
Malcisbo Ltd.'s support email address is info@malcisbo.com
Malcisbo Ltd.'s categories are Biotechnology Research
